For individuals with type 2 diabetes, anxiety symptoms affect mortality risk, independently of depression symptoms, and attenuate the excess mortality associated with depression.
Sitagliptin has a neutral effect on cardiovascular risk among older patients with type 2 diabetes.
Apolipoprotein (apo) CIII and apoCIII-to-apoA1 ratio are correlated with incident type 2 diabetes.
Consumption of single omega-3 is associated with an increased risk of type 2 diabetes, with dosage, ethnicity, trial duration, and recruited age influencing the effect.
Resistance to the antilipolytic effect of insulin is increased in obese individuals with normal glucose tolerance, and in those with impaired glucose tolerance and type 2 diabetes.
Patients receiving the highest dose of L. reuteri have increases in insulin sensitivity index vs baseline.
For patients with type 2 diabetes, the SGLT2 inhibitor luseogliflozin has similar efficacy when meals contain 40% to 55% total energy from carbohydrate.
The ACP has updated the 2012 guideline to provide clinical recommendations of oral pharmacologic treatment of type 2 diabetes.
Postprandial hyperglycemia is linked to cardiovascular disease in patients with type 2 diabetes, regardless of HbA1c.
Whites with type 2 diabetes have more life years lost than South Asians or blacks.